Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome

NCT04540120 is registered in ClinicalTrials.gov with Olatec Therapeutics, Inc. as lead sponsor.

NCT NCT04540120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04540120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
Lead sponsor
Olatec Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
September 24, 2020
Completion date
July 28, 2022
Enrollment
49 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, cytokine release syndrome